Research Participant Payments – IRS Reporting Update
Effective 1 January 2026 the IRS reporting threshold for research participant compensation rose from $600 to $2,000 per calendar year.
Read more →Regulatory updates, guidance summaries and news from the HRP team.
Effective 1 January 2026 the IRS reporting threshold for research participant compensation rose from $600 to $2,000 per calendar year.
Read more →Summary and sample information sheet on the IRS reporting threshold for research participant compensation, which rose from $600 to $2,000 in 2026.
Read more →This presentation reviews what "vulnerability" means when conducting human-subjects research. "Vulnerability" should be understood broadly and contextually — beyond just legally defined groups — and researchers must proactively identify and mitigate a variety of risks (e.g. power imbalances, coercion, confidentiality,…
Read more →The attached document provides a summary of the new rules from the U.S. Department of Justice (DOJ) and National Institutes of Health (NIH) that tighten controls on access to U.S. “bulk sensitive personal data” and government-related data — forbidding or…
Read more →Sample IRB guidelines for investigators whose human subjects research may be subject to a stop work or pause work directive from a federal funding agency.
Read more →This document provides a detailed side-by-side comparison of the regulations under Common Rule and current (and proposed) U.S. Food and Drug Administration (FDA) regulations (21 CFR 50/56 etc.), showing how FDA’s human-subjects-research and IRB requirements could be harmonized — or…
Read more →The document outlines proposed revisions (2022–2024) by U.S. Food and Drug Administration (FDA) to its human-subjects and IRB regulations (21 CFR 50, 56, and 812), aiming to harmonize FDA rules with the revised Common Rule — including updates to informed-consent…
Read more →A one page summary to clarify guidance on determining when CDS software is excluded from the definition of a “medical device” under section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Only software functions that meet all four specified…
Read more →Summarizes the changes to NIH Guidance for IACUC programs that are USDA registered – providing IACUCs greater flexibility in how they conduct semiannual program reviews and inspections.Download
Read more →This 3-page summary highlights key facts, background, and ORI Recommended Next Steps. Followed by summaries of the different subpart changes including definitions, responsibilities of institutions, and responsibilities of HHS.Download
Read more →The purpose of this overview is to explain a proposed U.S. Food and Drug Administration (FDA) rule that would create formal exemptions from investigational new drug (IND) requirements for certain clinical studies of products lawfully marketed as conventional foods, dietary…
Read more →The purpose of the document is to present key facts about the FDA’s new final rule — 21 CFR 50.22 — which allows an Institutional Review Board (IRB) to waive or alter some or all informed-consent requirements for certain clinical…
Read more →Read more →